196 related articles for article (PubMed ID: 27303825)
1. Hypoxia-Responsive Polymersomes for Drug Delivery to Hypoxic Pancreatic Cancer Cells.
Kulkarni P; Haldar MK; You S; Choi Y; Mallik S
Biomacromolecules; 2016 Aug; 17(8):2507-13. PubMed ID: 27303825
[TBL] [Abstract][Full Text] [Related]
2. Tissue-Penetrating, Hypoxia-Responsive Echogenic Polymersomes For Drug Delivery To Solid Tumors.
Kulkarni P; Haldar MK; Karandish F; Confeld M; Hossain R; Borowicz P; Gange K; Xia L; Sarkar K; Mallik S
Chemistry; 2018 Aug; 24(48):12490-12494. PubMed ID: 29968262
[TBL] [Abstract][Full Text] [Related]
3. Nucleus-Targeted, Echogenic Polymersomes for Delivering a Cancer Stemness Inhibitor to Pancreatic Cancer Cells.
Karandish F; Mamnoon B; Feng L; Haldar MK; Xia L; Gange KN; You S; Choi Y; Sarkar K; Mallik S
Biomacromolecules; 2018 Oct; 19(10):4122-4132. PubMed ID: 30169024
[TBL] [Abstract][Full Text] [Related]
4. Targeted polymeric nanoparticles for drug delivery to hypoxic, triple-negative breast tumors.
Mamnoon B; Loganathan J; Confeld MI; De Fonseka N; Feng L; Froberg J; Choi Y; Tuvin DM; Sathish V; Mallik S
ACS Appl Bio Mater; 2021 Feb; 4(2):1450-1460. PubMed ID: 33954285
[TBL] [Abstract][Full Text] [Related]
5. Acridine Orange Conjugated Polymersomes for Simultaneous Nuclear Delivery of Gemcitabine and Doxorubicin to Pancreatic Cancer Cells.
Anajafi T; Scott MD; You S; Yang X; Choi Y; Qian SY; Mallik S
Bioconjug Chem; 2016 Mar; 27(3):762-71. PubMed ID: 26848507
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-Responsive, Polymeric Nanocarriers for Targeted Drug Delivery to Estrogen Receptor-Positive Breast Cancer Cell Spheroids.
Mamnoon B; Feng L; Froberg J; Choi Y; Sathish V; Mallik S
Mol Pharm; 2020 Nov; 17(11):4312-4322. PubMed ID: 32926627
[TBL] [Abstract][Full Text] [Related]
7. Multifunctional polymersomes for cytosolic delivery of gemcitabine and doxorubicin to cancer cells.
Nahire R; Haldar MK; Paul S; Ambre AH; Meghnani V; Layek B; Katti KS; Gange KN; Singh J; Sarkar K; Mallik S
Biomaterials; 2014 Aug; 35(24):6482-97. PubMed ID: 24797878
[TBL] [Abstract][Full Text] [Related]
8. PEG-b-poly (carbonate)-derived nanocarrier platform with pH-responsive properties for pancreatic cancer combination therapy.
Ray P; Confeld M; Borowicz P; Wang T; Mallik S; Quadir M
Colloids Surf B Biointerfaces; 2019 Feb; 174():126-135. PubMed ID: 30447521
[TBL] [Abstract][Full Text] [Related]
9. Combinatorial and sequential delivery of gemcitabine and oseltamivir phosphate from implantable poly(d,l-lactic-co-glycolic acid) cylinders disables human pancreatic cancer cell survival.
Allison Logan S; Brissenden AJ; Szewczuk MR; Neufeld RJ
Drug Des Devel Ther; 2017; 11():2239-2250. PubMed ID: 28814832
[TBL] [Abstract][Full Text] [Related]
10. Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia.
Maftouh M; Avan A; Sciarrillo R; Granchi C; Leon LG; Rani R; Funel N; Smid K; Honeywell R; Boggi U; Minutolo F; Peters GJ; Giovannetti E
Br J Cancer; 2014 Jan; 110(1):172-82. PubMed ID: 24178759
[TBL] [Abstract][Full Text] [Related]
11. Dual-responsive polymersomes as anticancer drug carriers for the co-delivery of doxorubicin and paclitaxel.
Zhou D; Fei Z; Jin L; Zhou P; Li C; Liu X; Zhao C
J Mater Chem B; 2021 Jan; 9(3):801-808. PubMed ID: 33336680
[TBL] [Abstract][Full Text] [Related]
12. Targeting the Tumor Core: Hypoxia-Responsive Nanoparticles for the Delivery of Chemotherapy to Pancreatic Tumors.
Confeld MI; Mamnoon B; Feng L; Jensen-Smith H; Ray P; Froberg J; Kim J; Hollingsworth MA; Quadir M; Choi Y; Mallik S
Mol Pharm; 2020 Aug; 17(8):2849-2863. PubMed ID: 32521162
[TBL] [Abstract][Full Text] [Related]
13. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
14. Combining Gemcitabine-Loaded Macrophage-like Nanoparticles and Erlotinib for Pancreatic Cancer Therapy.
Cai H; Wang R; Guo X; Song M; Yan F; Ji B; Liu Y
Mol Pharm; 2021 Jul; 18(7):2495-2506. PubMed ID: 34078087
[TBL] [Abstract][Full Text] [Related]
15. Light-responsive polymersomes with a charge-switch for targeted drug delivery.
Zhou Y; Chen R; Yang H; Bao C; Fan J; Wang C; Lin Q; Zhu L
J Mater Chem B; 2020 Jan; 8(4):727-735. PubMed ID: 31894822
[TBL] [Abstract][Full Text] [Related]
16. Effects of obatoclax combined with gemcitabine on the biological activity of pancreatic cancer cells under hypoxic conditions.
Hou XF; Li S; Wu C; Li K; Xu SN; Wang JF
Mol Med Rep; 2018 Jul; 18(1):495-501. PubMed ID: 29749486
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of a gemcitabine-modified phospholipid and its subsequent incorporation into a single microbubble formulation loaded with paclitaxel for the treatment of pancreatic cancer using ultrasound-targeted microbubble destruction.
Logan KA; Nesbitt H; Callan B; Gao J; McKaig T; Taylor M; Love M; McHale AP; Callan JF
Eur J Pharm Biopharm; 2021 Aug; 165():374-382. PubMed ID: 34038797
[TBL] [Abstract][Full Text] [Related]
18. Quercetin potentializes the respective cytotoxic activity of gemcitabine or doxorubicin on 3D culture of AsPC-1 or HepG2 cells, through the inhibition of HIF-1α and MDR1.
Hassan S; Peluso J; Chalhoub S; Idoux Gillet Y; Benkirane-Jessel N; Rochel N; Fuhrmann G; Ubeaud-Sequier G
PLoS One; 2020; 15(10):e0240676. PubMed ID: 33052979
[TBL] [Abstract][Full Text] [Related]
19. Self-assembled nanoscale coordination polymers carrying oxaliplatin and gemcitabine for synergistic combination therapy of pancreatic cancer.
Poon C; He C; Liu D; Lu K; Lin W
J Control Release; 2015 Mar; 201():90-9. PubMed ID: 25620067
[TBL] [Abstract][Full Text] [Related]
20. Mmp-9 responsive PEG cleavable nanovesicles for efficient delivery of chemotherapeutics to pancreatic cancer.
Kulkarni PS; Haldar MK; Nahire RR; Katti P; Ambre AH; Muhonen WW; Shabb JB; Padi SK; Singh RK; Borowicz PP; Shrivastava DK; Katti KS; Reindl K; Guo B; Mallik S
Mol Pharm; 2014 Jul; 11(7):2390-9. PubMed ID: 24827725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
